Efficacy and safety of a multifactor intervention to improve therapeutic adherence in patients with chronic obstructive pulmonary disease (COPD): protocol for the ICEPOC study by Barnestein-Fonseca, Pilar et al.
STUDY PROTOCOL Open Access
Efficacy and safety of a multifactor intervention
to improve therapeutic adherence in patients
with chronic obstructive pulmonary disease
(COPD): protocol for the ICEPOC study
Pilar Barnestein-Fonseca
1*, José Leiva-Fernández
2, Francisca Vidal-España
1, Antonio García-Ruiz
3,
Daniel Prados-Torres
1, Francisca Leiva-Fernández
1
Abstract
Background: Low therapeutic adherence to medication is very common. Clinical effectiveness is related to dose
rate and route of administration and so poor therapeutic adherence can reduce the clinical benefit of treatment.
The therapeutic adherence of patients with chronic obstructive pulmonary disease (COPD) is extremely poor
according to most studies. The research about COPD adherence has mainly focussed on quantifying its effect, and
few studies have researched factors that affect non-adherence. Our study will evaluate the effectiveness of a
multifactor intervention to improve the therapeutic adherence of COPD patients.
Methods/Design: A randomized controlled clinical trial with 140 COPD diagnosed patients selected by a non-
probabilistic method of sampling. Subjects will be randomly allocated into two groups, using the block
randomization technique. Every patient in each group will be visited four times during the year of the study.
Intervention: Motivational aspects related to adherence (beliefs and behaviour): group and individual interviews;
cognitive aspects: information about illness; skills: inhaled technique training. Reinforcement of the cognitive-
emotional aspects and inhaled technique training will be carried out in all visits of the intervention group.
Discussion: Adherence to a prescribed treatment involves a behavioural change. Cognitive, emotional and
motivational aspects influence this change and so we consider the best intervention procedure to improve
adherence would be a cognitive and emotional strategy which could be applied in daily clinical practice. Our
hypothesis is that the application of a multifactor intervention (COPD information, dose reminders and reinforcing
audiovisual material, motivational aspects and inhalation technique training) to COPD patients taking inhaled
treatment will give a 25% increase in the number of patients showing therapeutic adherence in this group
compared to the control group.
We will evaluate the effectiveness of this multifactor intervention on patient adherence to inhaled drugs
considering that it will be right and feasible to the clinical practice context.
Trial registration: Current Controlled Trials ISCTN18841601
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As with all chronic diseases, non-adherence in patients
with COPD is common and contributes to adverse health
outcomes, reduced quality of life and increased health-
care expenditures [1]. According to the World Health
Organization (WHO), patient adherence to long term
therapy averages 50 percent [2]. Adherence rates in clini-
cal trials may be as high as 70 to 90 percent [3-5], but in
clinical practice it is in the range of 10 to 40 percent
[6-8]. In the Lung Health Study [3,9], therapeutic adher-
ence with inhaled treatment recorded by self-reported
methods after a one year follow-up was 60 percent and
decreased to 50 percent at the five year follow-up.
Despite the research about treatment adherence, few
factors have been associated with it [1]. Characteristics
of COPD medications and regimens can contribute to
non-adherence; several studies have reported that an
average of 60 percent of patients with COPD do not fol-
low the prescribed therapy [10]. Patients with COPD
often have medication for other pathologies and poly-
pharmacy is a common contributor to poor adherence.
Another factor is the frequency of dosing for every
drug, the more doses they have, the lower the adherence
can be. Patients taking multiple medications, each one
with a different dosing pattern, can be confused and fru-
strated by this and it can lead to forgetting to take med-
ications. The route of administration can also influence
adherence. The oral forms are easier and have higher
adherence than inhaled medications [11]. In addition,
mistakes in inhalation techniques are frequent and they
too affect adherence; several studies have reported that
up to 85 percent of patients use their inhaler ineffec-
tively [10]. Another problem is the drug’s efficacy;
adherence is higher to a drug whose pharmacological
effect is quick and has a direct impact on symptoms.
Additional factors can include adverse side effects and,
in some healthcare systems, the inability to pay or a
reduced access to medication [12].
There are factors related with patients that can influ-
ence adherence such as age. Adherence is often better
in older persons, but the increase of age is also asso-
ciated with comorbidity, polypharmacy, cognitive decline
and in some cases, with difficulty in reading small print
or to open and manage the devices. Another factor is
the patient’s disease perception that leads to the discon-
tinuation of therapy due to a lack of or excess of clinical
symptoms, inconvenient or expensive medication [12].
This perception is built up by the patient and also by
the healthcare provider and caregivers.
There are few studies about interventions to improve
therapeutic adherence in COPD patients and other
important aspects of the disease management. Most of
them have been joint studies with asthmatic patients
[13-18]. They have mainly focussed on quantifying the
adherence and not many have explored factors which
affect non-adherence, although the authors point out
the need for working in motivational and cognitive ways
to improve patients’ understanding of both their illness
and treatment [18].
Specific studies which consider educational programs
exclusively for COPD patients, show significant
improvement in patients’ management of disease, less
exacerbations, decrease in the rescue medication and
improved knowledge about inhaler use [15,17]. These
programs include information about the illness, the
treatment, the importance of the adherence, the man-
agement of exacerbation, instructions about the inhala-
tion technique, and recommendations about the proper
time to ask for doctor’s advice and, in some cases, coun-
seling to cease smoking or referrals to independent
programs.
Between 1998 and 2003 our research team carried out
a cohort study of patients with COPD in two health
centers in Malaga. The Batalla Test [19], the Morinsky-
Green test [20] and the self-reported compliance from
Haynes and Sackett test [21] were all included as treat-
ment adherence evaluation methods. We found little
consistent data. Between 2004 and 2006, we performed
another cohort study in 195 COPD patients from 4
health centers. Patients have been followed up during
1 year and we have used four therapeutic adherence
measures: the Batalla test, the Morinsky-Green test, the
Haynes-Sackett test and the dose/pill count. In this
study we selected the dose/pill count as the reference
method to measure adherence and we calculated the
diagnostic validity of the self-reported methods. We
found that the use of the Batalla test and the Morisky-
Green test together was the most reliable way to assess
adherence by self-reported methods and we proposed a
strategy to measure adherence in clinical practice
depending on the adherence prevalence [22]. Taking all
this into account, our next step in the study of adher-
ence was the design of a multifactor intervention to
improve treatment adherence in patients with COPD.
The main objective of this study is to evaluate the
effectiveness of a multifactor intervention (COPD infor-
mation, dose reminders, audiovisual material, motiva-
tional aspects and inhalation techniques training) to
improve the therapeutic adherence in COPD patients
with inhaled scheduled treatment after one year follow-
up with two reinforcement visits (3 and 6 month after
intervention). The second objective is to describe the
main factors related to adherence. The specific aims are:
- To evaluate in two study groups treatment adher-
ence prevalence with inhaled medication (primary
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three and six months and at one year after the
intervention.
-T oe v a l u a t et h ef u n c t i o n al status using a forced
spirometry and the quality of life (St George Respira-
tory questionnarie, EuroQoL-5D) and the clinical
progress (SeguiEPOC) as secondary outcome mea-
sures in both groups.
- To analyse the main factors related to therapeutic
adherence.
Methods
This study has been approved by the Ethical Commit-
tees of Distrito Sanitario Málaga (01/03/07) and Axar-
quía (13/05/08) and by Committee of Clinical Trials of
Hospital Clínico Universitario Virgen de la Victoria (30/
11/07). The study protocol was reviewed by Spanish
Medicine Agency and Sanitary products.
Participants
140 patients with COPD selected by a non-probabilistic
consecutive sampling method. The inclusion criteria
were searched in the patient’s clinical record as: having
been diagnosed of COPD by spirometry following the
SEPAR (Sociedad Española de Neumología y Cirugia
Torácica) guidelines [23], receiving clinical assistance in
primary care centers in Malaga area, having been pre-
scribed inhaled and scheduled treatment; and having
agreed to be part of the study by giving signed written
consent. Exclusion criteria: other respiratory conditions
which are not included in the COPD definition (bronch-
iectasis, asthma or cystic fibrosis) and cognitive impair-
ment problems registered in their clinical record
(Dementia, Alzheimer, Parkinson, Cognitive decline).
Sample size
it was calculated to detect an adherence percentage dif-
ference between the two groups of 25%, with a statistical
power of 80% and a confidence level of 95%, assuming a
percentage of expected losses of 15%. The final sample
size was 140 patients with COPD that meet the selec-
tion criteria mentioned above.
Design
Randomized controlled clinical trial. (Figure 1)
Setting
Primary Care
Outcomes
Primary outcome
the therapeutic adherence considered as the percentage
of patients classified as good adherent. The adherence
will be measure by three adherence measurements: the
Morinsky-Green test (MGT) [20], the Batalla test (BT)
[19] and the dose/pills count. We will consider as refer-
ence methods the results of dose/pill count. Each
method will be considered independently.
The MGT measures the attitude towards treatment
and it was adapted by us to inhaled medication. The
test has four questions and a patient will be considered
a good adherent when he answers properly the complete
questionnaire.
The BT provides information about the patients’
knowledge of their illness. The test has three questions,
adapted to COPD, and a patient will be considered a
good adherent when he answers properly the complete
questionnaire.
The dose/pill count is the number of pills or doses
taken divided by the number of pills or doses prescribed,
multiplied by 100 (expressed as a percentage). According
with Sackett et al. [21] recommendations, a good adher-
ence is considered when the result of counting is between
80% (a twenty percent of doses/pills missed) and 110%
(the patient inhales a ten percent more of doses/pills) of
dose/pill prescribed. This cutoff point was selected for
consistency with other studies [24-26].
We consider the dose/pill count as the more confident
method. We use the two self-reported methods because
they are easier to apply in clinical practice and, in a pre-
vious work conducted by us, we found acceptable indi-
cators of their validity as diagnostic test for treatment
adherence in COPD patients under certain environment
circumstances.
Secondary outcome
functional status (spirometry), quality of life (St George
respiratory questionnaire [27], and EuroQoL-5 D [28])
and the clinical progress with SeguiEPOC questionnaire.
Independent variables
age, sex, educational level, comorbidity, smoking history,
COPD severity grade (according to SEPAR guidelines
[29]), prescribed medication, family support (Family
Apgar Test [30]): social support (DUKE-UNC Test [31]).
Intervention
Activities
The intervention has two main activities: a group ses-
sion followed by individual visits.
Group session the session will last 2 hours including the
patient’s reception, the material distribution, the inter-
vention and the farewell. The intervention is structured
in three parts: the first part will be conducted following
the focus group methodology. The number of patients
will be about 6 to 9 per group. In the second part,
patients will receive information about their disease and
treatment with the aid of the distributed material. The
t h i r dp a r tw i l lb ec o n d u c t e da sat r a i n i n gs e s s i o na b o u t
inhalation technique.
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will depend on the topics related to adherence that we
will need to work with every patient. These encounters
will be videotaped to facilitate the collection of the data.
In addition to written informed consent including in the
recruitment visit, we will ask for their verbal informed
consent all the times that we will videotape a visit.
Intervention Content
The content of the intervention can be divided in three
elements that include the most relevant aspects related
140 Patients with COPD
Inclusion Visit
Randomization
Control Group
70 patients
Intervention Group
70 patients
Visit 1
(3 months after inclusion)
•Variables changes
•Treatment adherence
Visit 2
(6 months after inclusion)
•Variables changes 
•Treatment adherence
Visit 3
(12 months after inclusion)
•Sociodemographic profile
•Clinical characteristic
•Social support
•Family support
•Quality of life
•Variables changes
•Treatment adherence
•Sociodemographic profile
•Clinical characteristic
•Social support
•Family Support
•Quality of life
•Prescribed treatment
•Treatment adherence
Written Consent
Intervention
Motivational aspect
Cognitive aspects
Skills development
Visit 1
(3 months after intervention)
•Variables changes
•Treatment adherence
•Intervention reinforcement
Visit 2
(6 months after intervention)
•Variables changes
•Treatment adherence
•Intervention reinforcement
Visit 3
(12 months after intervention)
•Sociodemographic profile
•Clinical characteristic
•Social support
•Family support
•Quality of life
•Variables changes
•Treatment adherence
Group session
Figure 1 Study general graphic.
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tional and cognitive aspects, and skill development.
Motivational Aspects We mean to find out why the
recommended therapeutic regime is not accomplished, in
order to use the individual motivational aspects that could
improve the adherence over the next follow up visits.
This aspect of the intervention will be developed along
the first part of the group session and in the individual
visits with different methodologies. In the first part of
the group session, we will use qualitative methods by
the focus group technique to explore the beliefs and atti-
tudes of patients. In the individual visit, we will use this
knowledge to design individual interviews to work on
motivational aspects to try to improve treatment adher-
ence. These individual interviews will be conducted in
the follow-up visits (V1, V2 and V3).
Qualitative research methods have proved to be useful
in the health care field. These methods provide in-depth
knowledge about perceptions, beliefs and values of the
persons or groups involved [32]. Taking into account the
importance to explore behaviours and attitudes of our tar-
get population we consider the group interview (focus
group) will be the most adequate technique to gather the
information. These techniques explore dynamics interac-
tions between group members, consider issues that may
underlie individual preferences and explore areas of agree-
ment and dissent [33], to reveal patient’s experiences and
points of view about their illness and treatment.
The research team has determined the basic topics to
explore in the focus group. These are about adherence
and the strategies to cope with the disease, and they are
made as a semi-structured questionnaire (Figure 2). The
content of this questionnaire might be adapted depend-
ing on the findings that could arise during the develop-
ment of the focus group [33].
An interviewer and a collaborator will be present in
each group. They are both specially trained in qualita-
tive techniques and in the use of inhaler devices. The
training in motivational techniques has been done under
one of the project researcher’ss u p e r v i s i o nw h oi sa n
expert in communication techniques at the Teaching
Unit of Community and Family Medicine (Málaga).
The interviewer will introduce the study’s objective,
will explain the need to video-record the session and
will give information about data confidentiality. The
patients are asked for their consent to videotape the ses-
sion. After the group sessions the two investigators will
discuss their impressions and notes about each group.
The data will be extracted using a form designed by the
research team using the group session questionnaire. All
the participants’ opinions will be collected. Each group
will be reviewed and the data will be collected from the
videotape by at least two members of the research team.
After the data collection, these researchers will discuss
their opinions of each patient and will agree a motiva-
tional strategy for the individual visits.
In the individual interviews, we will work with the
patient on all aspects that we have detected in the focus
group using the techniques of the motivational inter-
view. These visits will be video-recorded and the data
will be collected in the same way as in the focus group
to design the strategy for the next follow-up visit.
Cognitive Aspects Information is given about the dis-
ease so the patients can get to know it better and be
more conscious about the importance of the scheduled
treatment.
We have designed an audiovisual presentation to inform
the patients about the most important issues of their ill-
ness and its treatment and a written dossier with the oral
presentation content which will be given to the patient.
In the follow-up visit we will ask the patient if he has
doubts about his illness or about the information he was
given in the group session. Any questions they have are
answered straightaway.
Skills Training In the group session, the patients will
receive inhalation technique training, about how they
use their inhalers, why a good technique is important
and will practice the proper technique according to
SEPAR guidelines [34]. The training in the use of inha-
ler devices has been done at the Pediatrics Pneumology
Service of Hospital Materno Infantil (Málaga).
We will perform training in three steps:
- Patients will be asked how they use their inhalers.
Using a variety of placebo inhalers, all of them will
demonstrate how they use them to the instructor.
- When all patients have done the demonstration,
the trainer will ask about the problems and mistakes
with each technique. At the beginning, these ques-
tions will be for individuals, but when all patients
have answered individually, the questions will be
made general and opinions can be expressed about
any demonstration.
- The trainer will demonstrate the proper technique.
Each device will be used and its technique will be
explained step by step. The importance of following
the correct technique every time the patient uses the
inhaler device will be emphasized.
Finally the patients can ask questions and they will
practice the techniques until they are correct or until
the patient becomes tired.
In the follow-up visits we will review the inhalation
technique and we will solve any mistake or doubt as
explained previously. The objective here is for the
patients to identify their mistakes, and if they cannot, to
r e m i n dt h e mt h ep r o p e rt e c h n i q u eb ya sm a n yd e m o n -
strations as are necessary.
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Patients will be contacted using their health center
records. They will be invited to participate in the study
after a brief explanation by telephone about the research
aims and they will receive an appointment in the health
center. At this first appointment (inclusion visit)
patients will receive more detailed information about
the study and if they agree to participate, they will sign
the written consent.
At this point, subjects will be divided randomly into
two groups using the block randomization technique.
The blocks consist of 4 patients, two subjects per group
Interview script 
Good morning/afternoon. My name is …… I would like to thank you for your assistance and 
your participation in this study. The meeting will be approximately two hour.   
 
We are carrying out a study about the treatment in patients with COPD. In the first part of this 
meeting we attempt that you talk freely about this issue your experiences and point of view 
concerning COPD as start point. After this, we are going to identify everything that will be 
appearing as the conversation develops.  
 
We request your permission to videotape the interview. This is for practical reason, so we can 
compile all the information from this meeting. We guarantee the confidentiality of all contents 
and they can only be used by the researchers.  
 
You can talk whenever you wish, but, please, do not talk at the same time so that all the 
conversations can be heard clearly. 
 
If you want, we can start by all saying our names, how long you have been a COPD patient and 
what do you think caused your COPD….  
 
Interview basic topics 
-  Do you take your medication as your doctor tells you? Do you take the doses/pill 
number prescribed? 
-  Do you feel confidence with your physician? Do you understand the things he says? 
Do you ask him what you do not understand? 
-  Do you think is a lifelong disease? 
-  Do you think your medication is useful? How do you think that it is beneficial to you? 
Do you think there is a better treatment? 
-  Do you have difficulty taking your inhaler? Do you feel that the inhaler is easy to 
use? 
-  Do you feel your medication works? Do you feel when the device is empty? 
-  Do you sometimes stop taking your inhaled medications? For example in summer 
or when you feel better or if you feel worse after you take your inhaler. 
-  Do you know the medical effect of the drug contained in the device or in the pill? 
-  Who is the responsible of your medication intake? Why? 
-  How do you feel when you need to take several medications at the same time? 
When this occurs is your life affected by this situation? Which one of the 
medication you take, do you think is essential or which one do you never leave 
out?  
Figure 2 Focus group interview script.
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(ICIC); (ICCI); (CIIC). Consequently, the numbers in
the two groups never differ at any time by more than
two. The blocks will be marked with a number from 1
to 6 and we will choose blocks at random to create the
allocation sequence using a sequence of random num-
bers generated by Microsoft Excel 2003 program with
the function fx:RAND(). We will need 35 random
blocks; and the final list of the included patients in each
arm of the trial will be set in advance. The researcher
who will allocate the patient will have the open-list of
randomization, but there will be no change of patient
group related with the subjects characteristics. Because
the patients are from 6 health centers, the randomiza-
tion and the presence of the intervention and control
subjects in all the health centers will be guaranteed.
After randomization all the study data will be
recorded and the adherence will be measured in both
groups.
Follow up
Control Group
they will be appointed for:
Visit 1: It will take place 3 months after the inclusion.
It will involve the measure of adherence and other vari-
able changes.
Visit 2: It will take place 6 months after the inclusion.
It will involve the measure of adherence and other vari-
able changes.
Visit 3: It will take place after 1 year follow up. All the
study data will be recorded including treatment
adherence.
There will be a pre-adherence visit before each follow-
up visit except for the inclusion one. The reason for the
pre-adherence visit is to ask the patient to bring a new
container that will be marked with the date in which it
is opened in order to count doses/pills through the
month. This is done because most of the devices that
patients use last 30 days. The pre-adherence visit will be
done by telephone to guarantee the follow-up.
Intervention Group
After the inclusion, the first part of the intervention
(group session) will be carried out in each health center
and the intervention group will receive appointments for:
Visit 1: It will take place 3 months after the interven-
tion. It will involve the measure of adherence and other
variable changes, encouragement about inhalation tech-
niques and motivational aspects related to treatment
adherence.
Visit 2: It will take place 6 months after the interven-
tion. It will involve the measure of adherence, other
variable changes and encouragement about inhalation
techniques and motivational aspects related to treatment
adherence.
Visit 3: It will take place after 1 year follow-up. All the
study data will be recorded and encouragement about
inhalation techniques and motivational aspects related
to treatment adherence.
There was a pre-adherence visit prior to all visits as
explained previously.
Adherence will be measured at each visit to control its
evolution during the follow-up period. All individual fol-
low-up visits will be videotaped to identify the motiva-
tional aspects and skills which each patient needs to be
applied at the next visit.
Statistical Analysis
A descriptive statistical analysis will be performed for all
the study variables. We will calculate the mean, median
and standard deviations for quantitative variables, and
t h ea b s o l u t ea n dr e l a t i v ef r e q u e n c yf o rq u a l i t a t i v e
variables.
The 95% confidence level will be applied. The analysis
will be made under an intention-to-treat procedure. The
between-group comparison for the primary outcome
will be explored using the Chi Square Test. The Relative
Risk Reduction (RRR), the Absolute Risk Reduction
(ARR) and the Number Needed to treat (NNT) will be
calculated. Inferences for the secondary outcomes will
be made using an analysis of variance (ANOVA). Finally
a logistic regression model will be performed for the pri-
mary outcome [treatment adherence (yes/not)], consid-
ering the intervention as the predictive variable and the
rest of the independent measures as the possible modi-
fying factors. We will use the usual 5% significance level
(a = 0.05) and the SPSS statistical package, version 15.0,
to run the proposed analysis.
Study limitations
The main study limitation is the selection bias due to
the missing data. In order to diminish this bias, we will
apply several strategies:
-A ni n c r e a s eo f1 5 %i nt h es a m p l es i z e( e x p e c t e d
losses)
- Three phone calls at different days and times for
unreachable patients
- Rescue appointments for the non-assistants to vis-
its (three different appointments)
Other aspect is the Hawthorne effect along the study
(ie, tendency of subjects participating in a research
study to change their behaviour). Although this could
affect overall estimates the adherence, the implications
might be less important in comparing results of different
measurements tools (unless, of course, the effect is dif-
ferentially captured by each measurement tool); further-
more, it is difficult to perceive that any potential
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months of study.
In addition we take into account the possible contami-
nation between the control and the intervention group
because of the relationship between subjects in their
daily life (neighborhood, relatives, social networks or
associations). However, in another educational interven-
tion study performed with obese patients in our area we
did not find a significant level of this effect [35]. We
also believe that the intervention characteristics (several
steps, small groups and individual visits) that we have
described will have little influence on contamination
between groups.
Another important aspect to consider is the protocol
and the intervention standardization. This is why the
dynamic has been structured in an exhaustive way and
the intervention will be performed by two professionals
trained in communication, disease knowledge and inha-
lation techniques of the different devices used by COPD
patients. Furthermore, we have designed a manual for
the researchers where we explain the working plan, the
different parts of intervention (the group session and
the individual visits), the protocol scheme to know what
they have to measure each time and the details to asses
each variable included in the study. In this way, the pro-
cedure can be replicated elsewhere.
Discussion
We have described the treatment adherence in a group
of patients in the Málaga area in the previous studies
and we have tried to validate easier and faster methods
than the dose/pill count, to evaluate the non-adherence
magnitude in these patients. From the results of this
previous work we have learnt to measure better the
treatment adherence. Once we have described the pro-
blem, the next step is to design a strategy to improve it.
There is little evidence about the use of strategies to
improve adherence in COPD patients. However the
non-adherence magnitude in these patients is high and
it affects directly their objective and subjective health
outcomes. Therefore we believe that the design and
development of an intervention to improve adherence in
COPD patients is very important to reach this purpose;
we also need to analyze deeply the motives and barriers
or difficulties that these patients have to comply with
the recommended medication regimens.
Adherence to the prescribed treatment involves a
behavioral change. Cognitive, emotional and motiva-
tional aspects have an influence on this change so this is
the reason why we consider that the best intervention
procedure to improve adherence would be a strategy
that takes into account cognitive and emotional aspects
of patients and that could be applied in the daily clinical
practice.
Our hypothesis is that the application of a multifactor
intervention to COPD patients under scheduled inhaled
treatment will increase up to 25% the percentage of
adherent patients in this group in comparison to the
control group. This intervention could be feasible to
implement in the clinical practice context. With this
strategy we try to promote patients’ autonomy and
responsibility about their disease, achieving in this way a
greater improvement on their health outcomes and
increasing clinical effectiveness in our daily practice.
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